From Yesterday: New Research Suggests That Questcor's Acthar Reduces Proteinuria in Idiopathic Membranous Nephropathy In Part Through Suppression of Anti-PLA2R Antibodies

On November 10 at the American Society of Nephrology 44th Annual Meeting, Boston University Assistant Professor of Medicine Laurence H. Beck, Jr., M.D., Ph.D. will present results from a study which found that H.P. Acthar® Gel may induce a remission of proteinuria in patients with idiopathic membranous nephropathy by suppressing production of antibodies to the phospholipase A2 receptor. iMN is a common cause of nephrotic syndrome in adults. Nephrotic syndrome is a known risk factor for progression to end-stage renal disease. Questcor

markets H.P. Acthar® Gel (repository corticotropin injection), which is indicated for the treatment of acute exacerbations of multiple sclerosis in adults, and as monotherapy for the treatment of IS in infants and children under 2 years of age.